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Pompe disease is a single disease continuum that includes variable neuromuscular symptoms
and rates of progression. However, specific clinical features, such as an early onset of respira-
tory problems preceding limb muscular weakness, distinguish Pompe disease from other neuro-
muscular diseases in which respiratory insufficiency occurs after loss of ambulation. The
management of Pompe disease also differs from other neuromuscular diseases in that specific
treatment is now available, making early recognition of the disease a priority. The results from
clinical trials with recombinant human acid a-glucosidase have been published, and they show
promising results with regards to the improvement of respiratory function in patients with
Pompe disease.
This review aims to give an overview of Pompe disease and to describe the current concepts
of the disease. A focus is placed on the pathophysiology and clinical presentation of respiratory
muscle involvement in adults. Additionally, new approaches and therapies available for the
management of respiratory complications observed in Pompe disease are discussed in detail.
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Pompe disease
Pompe disease, also termed glycogen storage disease type
II or acid maltase deficiency, is a serious and often fatal
condition of glycogen metabolism.1 The disease is an
autosomal recessive disorder, which manifests clinically as
a progressive neuromuscular disease and presents varying
rates of progression.1 Pompe disease is a single disease
continuum occurring at any age with remarkable pheno-
typic variation, as well as variable rates of progression and
extent of organ involvement.1,2 The prevalence of Pompe
disease is estimated to vary between 1 in 40,000 and 1 in
600,000, depending on geographical and ethnic factors.3,4
Originally described by, and named after, Dr J. C. Pompe in
1932, the disease is characterized by the lysosomal accumu-
lationofglycogen innumerous tissuesofaffected individuals.1
Massive glycogen deposits occur as a result of defects
in the activity of the glycogen degrading lysosomal enzyme,
acid a-glucosidase (GAA).1 Clinical presentation and disease
severity are primarily determined by the amount of residual
GAAenzymeactivity,with themost severely affectedpatients
having no detectable enzyme activity.5 No strict relationship
exists between genotype and phenotype;2 only a few muta-
tions have been described which are common in specific
ethnic groups.1,2 Additionally, metabolic factors can also be
involved, as a few patients have been identified with a mild
phenotype, but little functional GAA in their lysosomes.5
In symptomatic patients, the diagnosis of Pompe disease is
basedon lowGAAactivity in skinfibroblasts orblood samples.5
Additionally, muscle biopsy, although more invasive, can be
used for the determination of GAA activity or for histological
studies. However, the site of biopsy can influence results due
tovariability in glycogencontent betweenmuscles.5 A genetic
profile confirms the diagnosis of Pompe disease.5
Respiratory involvement
Respiratory involvement in Pompe disease differs from other
inherited neuromuscular diseases, especially Duchennemuscular dystrophy.6 In contrast to other neuromuscular
diseases, where respiratory insufficiency occurs after loss of
ambulation, respiratory symptoms in Pompe disease can be
one of the first clinical manifestations of the disease, and
patients may present respiratory impairment despite still
ambulating.6 A recent case study described a patient with
Pompe disease that walked into a clinic carrying his artificial
respirator.7 Similar to other neuromuscular diseases, reduced
vital capacity andweakness of theexpiratorymuscles result in
reduced cough and ineffective clearance of airway secretions
leading to recurrent chest infections.5,8 Diaphragm weakness
with sleep disordered breathing and respiratory failure also
seem to be an inevitable part of the Pompe disease
course.5,6,9,10 Respiratory failure in patients with Pompe
disease can range from insidious to acute onset.8,11e13 Cases
cited in the literature have reported symptoms of fatal
obstructive sleep apnea,11 and hypoventilation.11,14 Respira-
tory muscle involvement is the most common cause of early
death in patient’s with Pompe disease, as well as in other
patients with primary neuromuscular disease.9
Objective of this review
Due to the low prevalence and wide range of symptoms,
Pompe disease is often unrecognized by physicians, and the
majority of patients eventually die from complications of
respiratory muscle weakness. Therefore, as treatment with
enzyme replacement is now available, this review is
intended to enhance recognition of Pompe disease by pul-
monologists and other physicians.
This review will discuss the pathophysiology and clinical
presentation of respiratory muscle involvement seen with
Pompe disease, and will inform physicians involved in the
treatment of these patients about the new approaches and
therapies that are available for the management of respi-
ratory complications.
Methodology
A MEDLINE search was carried out using the key-terms
‘Pompe disease’, ‘acid maltase deficiency’, ‘glycogen
Pulmonary aspects of Pompe disease 479storage disease’, ‘respiratory’, and ‘pulmonary’. The
literature search was performed without time constraints in
order to ensure that all existing literature on the pulmonary
aspects of Pompe disease was found.
Results
Clinical symptoms and respiratory aspects of
Pompe disease
In general, muscle weakness in Pompe disease is symmet-
rical but imbalanced across joints, with greater weakness in
proximal muscles rather than distal, and lower extremities
rather than upper.1 Muscles can look hypertrophic and feel
firm to the touch despite profound weakness.1 Further-
more, respiratory muscles and the diaphragm are affected;
hence respiratory dysfunction that affects sleep, daily life
activities, and quality of life is common in the course of
neuromuscular disorders.15
The clinical symptoms of Pompe disease show a signifi-
cant variability with respect to age of onset, extent of
organ involvement, and rate of progression.1,15 A retro-
spective chart review by Kishnani et al.16 reported that in
infants, the median age of symptom onset was 2 months,
the median age at diagnosis was 4.7 months, and the
median age at death was 8.7 months. In older children and
adults, Pompe disease has a wider range of age of onset,
and a slower rate of progression.17,18 In adults, the first
symptoms start at a mean age of 28 years17,19 and were
mostly related to mobility problems and limb-girdle
weakness.17 The delay in diagnosing Pompe disease is
generally too long; more than 5 years for over half of the
adults studied.17,19 On average, adult patients with Pompe
disease start mechanical ventilation at the age of
50 years,15,17 which is 10 years later than the average age
of diagnosis. Combined with the finding that many patients
start mechanical ventilation during an episode of acute
respiratory failure,15 at diagnosis, patients should be
referred to a pulmonologist for regular evaluation and
timely initiation of respiratory aids when necessary, to
avoid potentially catastrophic situations during acute
chest colds.
Symptoms in infants
Prominent features of infantile Pompe disease are cardiac
muscle involvement and heart failure.20 All affected infants
have general muscle weakness, the so-called ‘floppy baby
syndrome’, and they certainly always have some respira-
tory muscle involvement.1,16e18,20 Any situation that
requires an increase of alveolar ventilation/respiration,
such as fever and/or a simple upper airway infection, is
therefore unmasking the underlying insufficiency.1,21
Marsden22 reported that disease progression was charac-
terized by increased respiratory distress in 72% of cases
examined. Additionally, respiratory failure was a common
sign noted on physical examination.22
In summary infantile Pompe disease is the most severe
subtype, and without treatment, the disease course is
rapidly progressive and fatal, with death due to cardiac
failure occurring before the age of 2 years.1Symptoms in patients with childhood- and
adulthood-disease onset
The primary symptom of Pompe disease in about one third
of adult cases is respiratory failure (or symptoms that
indicate respiratory insufficiency, such as dyspnea on
exertion, reduced physical capacity, recurrent pulmonary
infections, etc.).1,12,13,19,22,23 However, the onset of respi-
ratory involvement in adults may be very subtle, and
a thorough review of the literature reveals that respiratory
symptoms were preceded by slight limb muscular weakness
(e.g. inability to run, un-athletic appearance, etc.).1,24
In two-thirds of patients, respiratory symptoms increase
with Pompe disease progression and include a progressive
loss of respiratory muscle function, decrease of vital
capacity, sleep disordered breathing, impaired cough,
chronic respiratory insufficiency, and finally cor pulmonale,
and acute respiratory failure.6,11,14,15,18,25
In contrast to Pompe disease in infants, disease
progression in older children and adults is generally slower,
and although the skeletal muscles are predominantly
affected, ambulation is often preserved for years.1,11 The
respiratory muscles involved are the upper airways, inspi-
ratory muscles of the chest, and the diaphragm.5 In some
patients with Pompe disease, involvement of the upper
airways might lead to obstructive sleep apnea that might
be independent from the involvement of the other respi-
ratory muscles.8 However, predominat involvement of the
diaphragm and its progressive weakness is the character-
istic feature in these patients.
Depending on the severity of the diaphragmatic
weakness and the reduction of the vital capacity respira-
tion is compromised in a typical pattern. At first, res-
piration is only compromised during sleep, presenting as
nocturnal hypoventilation during REM-sleep which is mostly
pronounced due to physiologic atonia of chest wall muscles
and dependency of respiration on the diaphragm. Patients
are presenting with symptoms of unrestful sleep, nocturnal
awakening with dyspnea, nightmares and morning head-
aches due to hypercarbia, etc.5,8 When Pompe disease
progresses, patients develop hypoventilation during the day
(CO2 >45 mmHg), and in the end stages, also hypoxemia
(PO2 <60 mmHg), cor pulmonale and death.
5,8 During this
chronic course, the situation might exacerbate at any time
due to a respiratory infection, fever, injury, or surgery.5,8 In
addition, patients with Pompe disease present with acute
or chronic respiratory failure because of their inability to
adequately increase respiration.5,8 In the latter stages of
the disease, reduced vital capacity and weakness of the
expiratory muscles result in reduced cough and ineffective
clearance of airway secretions, leading to recurrent chest
infections.5,8
Respiratory evaluation of patients with
Pompe disease
Although there is a weak relationship between respiratory
and locomotor functions in adults with Pompe disease,
respiratory function should be monitored independently
from the degree of peripheral muscle weakness.15 The
respiratory status of patients with Pompe disease should
480 U. Mellies, F. Lofasobe evaluated at each physician or hospital visit, since
deterioration can occur continuously or in a stepwise
manner.6,8 Attention should especially focus on the ability
of the patient to cough, shortness of breath, exercise
tolerance, energy level, and degree of fatigue-ability.5 In
addition, a patient’s history should include the frequency
and severity of lower airway infections, sleep quality,
snoring, observed apneas, and morning headaches.
Respiratory function testing should differentiate inspi-
ratory and expiratory weakness and/or upper airway
muscle involvement.6 Based on the shape of the normal
pressure-volume curve, one would expect a considerable
loss of respiratory muscle strength before observing a fall in
vital capacity (VC) and other lung volumes.26 Actually, the
relationship between VC and maximal pressures generated
by the inspiratory muscle is more linear than curvilinear in
the Pompe disease population.15 Therefore, a decrease in
VC is an early sign of respiratory impairment, and routine
evaluation to assess pulmonary function should include VC
measurement with spirometry.6 It is very helpful to study
the change in VC that occurs when patients with Pompe
disease switch from the upright to the supine position,
which gives a simple index of diaphragm weakness relative
to the other inspiratory muscles.27 e which is a character-
istic feature in Pompe disease.6 Thus, a normal supine VC
excludes clinically relevant inspiratory muscle weakness.28
Periodic assessment of VC is important because thresholds
of VC have been shown to predict treatment complications
and outcomes in patients with neuromuscular disease.6
Some physicians consider maximum insufflation capacity as
a better prognostic factor than VC in neuromuscular
patients.29e31 Sniff inspiratory nasal pressure and maximum
inspiratory mouth pressure are both complementary tech-
niques that are non-invasive volitional maneuvres. These
techniques give a measurement of inspiratory muscle
strength; predicted normal values adjusted for age and sex
are available for both adults and children.26,32
Transdiaphragmatic pressure measurement requires
esophageal pressure and gastric pressure measurements,
but it has the advantage of directly quantifying diaphrag-
matic weakness.15,26,28 This quantification can be estab-
lished by asking the patient to do volitional maneuvres and,
when these maneuvres are equivocal, by stimulating the
phrenic nerve.15,26,28 Effective cough, and the different
methods that might assist it, can be appreciated by the
ability to generate expiratory airflow during peak flow or
cough maneuvres.33e35 Effective cough is considered
adequate when peak cough flow it is >200 L/min in both
adults36 and children,34,35 although a recent study indi-
cated that values <255 L/min could predict the risk of an
ineffective spontaneous cough during a respiratory tract
infection.37
Gas exchange and acid-base status should be also be
evaluated to assess the functional consequence of respi-
ratory muscle weakness26 and the development of respira-
tory failure. However, factors other than muscle weakness
can contribute to hypercapnia, such as abnormalities of the
chest wall that increase the elastic load imposed on the
inspiratory muscles of neuromuscular patients,38 and which
can be partially reversed with mechanical ventilation in
Pompe disease.39 Elevation of bicarbonate concentration
(>4 mmol/L) can provide an important clue on theoccurrence of nocturnal hypercapnia.26,40 Chest radio-
graphs can prove useful for diagnosis of clinical deteriora-
tion or of hypoxemia incompletely explained by alveolar
hypoventilation.5 Basal atelectasis is frequently observed12
and is explained by the disproportionate weakness of the
diaphragm. In addition, all patients suspected of Pompe
disease should give a detailed history of their sleeping
patterns at diagnosis and during follow-up appointments.5,6
Sleep studies (polysomnography [PSG]) should be
undertaken regularly in order to detect sleep disordered
breathing. Pompe disease patients with a VC of <60% of
predicted when in the supine position might have sleep
disordered breathing (typical desaturations during REM
sleep).6 A VC of <40% is a strong predictor for continuous
nocturnal hypoventilation, and a VC of <25%, for respira-
tory failure.5,6 Therefore, in advanced disease, screening
with overnight pulse-oxymetry could be sufficient to detect
nocturnal hypoventilation.5 Although PSG is the gold stan-
dard, it is not generally available, but should be performed
when symptoms are suggestive and when the VC (supine)
is <60% of predicted.5Respiratory interventions/treatments
Treatment of respiratory symptoms or respiratory support
might be necessary because the prognosis of untreated
chronic respiratory failure is poor in patients with Pompe
disease.11 Two techniques designed to assist breathing
during failure of the respiratory muscles have been
described in the literature: non-invasive positive pressure
ventilation (NIPPV); and assisted coughing.8 NIPPV has
emerged as the standard therapy for acute and chronic
respiratory failure despite the lack of prospective random-
ized trials.8 NIPPV can be used for managing most patients
with Pompe disease, including those with extremely low or
unmeasurable VC.8 However, some patients cannot be
managed by NIPPV, and tracheotomy is then required.8
Although the impact of long-term NIPPV on survival has been
demonstrated, there is much debate regarding the appro-
priate time for the introduction of either intermittent or
continuous NIPPV, i.e. instituted for permanent respiratory
failure versus nocturnal hypoventilation.11 Patients with
nocturnal hypoventilation and sleep apnea syndrome are
likely to benefit from the timely introduction of NIPPV by
having significantly improved sleep and a reduction in
daytime symptoms, such as morning headaches, lack of
appetite, sleepiness, and impaired concentration.8
To remove respiratory secretions in patients with inef-
fective cough capacity, several groups have evaluated
cough augmentation methods based on mechanical hyper-
inflation techniques,29e31,33,34,41 and/or manual and/or
mechanical expiratory assisted coughing.31,33 These tech-
niques, and especially the mechanical insufflatoreexsuf-
flator, might be of benefit in order to assist clearance of
airway secretions, avoiding tracheostomy for secretion
clearance or ventilatory failure in patients with Pompe
disease with insufficient cough due to neuromuscular
disease.8 In patients with Pompe disease, inspiratory
muscle weakness is more pronounced than expiratory
weakness and, therefore, assisted coughing will not reduce
the need of NIPPV in these patients.
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in patients with neuromuscular disease with pre-existing
respiratory compromise.8 Therefore, the prevention of
chest infections should be a major goal of treatment,
and the clearance of mucus secretions from airways and
maintenance of sufficient cough are measures that can be
used to reduce the frequency of chest infections and
hospital admissions.35 Proactive monitoring and treatment
programs, including regular assessments of lung function
and early antibiotic treatment, are likely to improve
outcome and quality of life for many patients with Pompe
disease.8
Management issues during anesthesia
The progressive infiltration of glycogen in the heart
and skeletal muscle results in a severe form of cardiomy-
opathy and respiratory muscle weakness.42 As a result, the
anesthetist faces significant problems in the management
of patients with Pompe disease.42 Pre-operatively, the
question of whether the benefit of surgery justifies the
anesthetic risk must be raised. A thorough pre-operative
examination should include the detection of associated
cardiac and respiratory dysfunction.43 Anesthetic experi-
ence in Pompe disease is limited because of the short
life expectancy.42,44,45 McFarlane and Soni42 described
a patient who had a cardiac arrest after induction with
inhaled halothane and subsequently underwent a safe
anesthesia with ketamine. Kotani et al.44 reported their
experience with a general anesthetic administered to an
11-year-old boy with severe Pompe disease. The patient
received enflurane and N2O to eliminate the need for intra-
operative administration of muscle relaxants or other drugs
that cause respiratory depression.44 However, the boy had
post-operative respiratory failure and required ventilator
support.44 The authors concluded that the administration
of a volatile anesthetic and the avoidance of muscle
relaxants do not protect patients with Pompe disease from
post-operative respiratory failure.44 Additionally, Kotani
et al.44 emphasized that post-operative respiratory failure
should be anticipated for all patients with Pompe disease
undergoing a general anesthetic, regardless of the anes-
thetic drugs used.
Key factors in successful anesthesia outcome are
attention to anesthetic technique and close monitoring.42
Given the high propensity toward myocardial ischemia,
a five-lead electrocardiogram (ECG) with continuous
ST-segment monitoring and placement of an indwelling
arterial catheter should be strongly considered.45
Management of patients with Pompe disease
In general, adults with Pompe disease report significantly
poorer quality of life than the general population on
the physical functioning, general health, vitality, and social
functioning scales.46 More specifically, wheelchair use is
associated with lower physical and social functioning
scores, and the use of artificial ventilation with lower
physical functioning scores.46
Physical therapy, such as gentle facilitation of move-
ment with active, graded assistance in infants, and aerobicfunctional exercise with active assistance in adults
might preserve motor and physiologic function in patients,
as well as maximizing the benefits of enzyme replacement
therapy.47
Net muscle protein degradation in adults affected by
Pompe disease is believed to be a major contributing factor
to the muscle weakness and wasting of the disease.48 The
combination of nutrition and exercise therapy, designed to
decrease muscle glycogen deposit and to increase muscle
fatty acid utilization, has been reported to slow the
progression of Pompe disease.48 However, the beneficial
effects of nutrition and exercise therapy for adult patients
with Pompe disease needs to be confirmed in a large,
prospective, randomized, multicenter study, with careful
monitoring of compliance by caregivers.48
Enzyme replacement and other emerging
therapies
Enzyme replacement therapy
Recently, alglucosidase alfa (recombinant human GAA,
Myozyme; Genzyme Corporation, Cambridge, MA, USA)
was approved by the European and US authorities for the
treatment of Pompe disease (20 mg/kg body weight
administered every 2 weeks as an intravenous infusion).
Patients across the spectrum of Pompe disease (infants,
juveniles, and adults) have been treated with alglucosidase
alfa in clinical trials, case series, and case studies.
Clinical studies in infants have shown that early treat-
ment with alglucosidase alfa is associated with improved
response.24,49 The safety and efficacy of alglucosidase
alfa treatment has been evaluated in a clinical trial of 18
severely affected infants with Pompe disease who began
treatment before 6 months of age.49 Kishnani et al.49
reported that treatment with alglucosidase alfa in infants
resulted in a reduced risk of invasive ventilation and of any
type of ventilation (92 and 88%, respectively), compared
with an untreated historical control group. All 18 patients
in this open-label study were alive at age 18 months
(100%) compared with 1.9% (95% CI 0e5.5%) in an untreated
historical control group.49 A second trial included 21
older infants with Pompe disease aged between 6 and
36 months.50 During the first year of therapy with algluco-
sidase alfa, 76% of infants with Pompe disease survived, 83%
of patients showed a reversal of cardiomyopathy, and 48%
acquired new motor mile stones.50 Comparing these results
with the 100% survival in infants treated before 6 months
of age suggests better outcomes with early treatment.
In both infants and adults, it has also been shown that
the response of muscle and respiratory functions to alglu-
cosidase alfa therapy seems to be related to the condition
of the affected patient at baseline.24,51 A study by Van den
Hout et al.52 reported the respiratory course of four
patients with Pompe disease before and after alglucosidase
alfa treatment. The four patients in this study responded
differently to the treatment, although the age of the
patient at the start of treatment and symptoms at inclusion
seemed to play a role in outcome.52 The two younger
patients (aged 2.5 and 3 months) showed no significant
respiratory symptoms at inclusion. However, one of the
482 U. Mellies, F. Lofasopatients became ventilator dependent at the age of 2 years
after a surgical procedure. The second patient had an
uneventful respiratory course. The two older patients
started treatment when they were aged 7 and 8 months.
Both remained ventilator dependent, even though other
symptoms improved during treatment with alglucosidase
alfa.52 Thus, early recognition of symptoms and a confirmed
diagnosis of Pompe disease are crucial in order to achieve
optimal therapeutic benefit for patients.
Alglucosidase alfa has also been studied in juveniles
and adults with Pompe disease. Van der Ploeg and
Marsden51 recently presented the outcomes of 18 severely
affected juvenile and adult patients with Pompe disease
who were treated with alglucosidase alfa. Ten patients
demonstrated improvements in respiratory function.51
A preliminary report of a study in patients with Pompe
disease by Van der Ploeg et al.53 showed that in five
patients, with a median treatment age of 12 years (range
5e15 years), improvements in respiratory function and
motor function were observed after 38 infusions of alglu-
cosidase alfa.53 In a study of five ventilator-dependent
patients with a mean  SD age of 48  14 years, at week 52
of treatment with alglucosidase alfa, two patients were
able to breath without a ventilator (1 and 2 h/24 h), and
two showed mild improvements in slow VC sitting
and supine, maximal inspiratory and expiratory pressures,
and transdiaphragmatic pressures.54 Preliminary results
from the Late Onset Treatment Study (LOTS), a multi-
center, randomized, double-blind, placebo-controlled trial
on the efficacy and safety of alglucosidase alfa in 90 pedi-
atric and adult patients >8 years, showed improvements in
walking and pulmonary outcomes compared with placebo.
By 78 weeks, a mean absolute difference of 3.4  1.2% in
percentage predicted forced VC was observed in favor of
alglucosidase alfa (PZ 0.003) (baseline mean forced VC
was 54.6  14.8%).55 The availability of an effective treat-
ment emphasizes the importance of early diagnosis and
early initiation of treatment in Pompe disease.
Other therapies
Other therapies indevelopment forPompedisease include the
experimental adeno-associated virus vector-mediated gene
therapy and putative chemical chaperones such as deoxy-
nojirimycin.56,57 Both experimental therapies hold promise
for the availability of a curative therapy.56,57 In preclinical
studies, Okumiya et al.57 demonstrated that chemical chap-
erones could mobilize mutant lysosomal GAA species that are
trapped in the endoplasmic reticulum and Golgi compart-
ments, and partly restore their catalytic function.
Necessity to evaluate treatment of patients with
Pompe disease
Longitudinal collection of patient data, whether or not
they receive specific treatment, is essential in order to
increase our understanding of Pompe disease and to
monitor patients, with the ultimate goal of improving the
management and the clinical outcome of patients. The
Pompe Disease Registry (http://www.pomperegistry.com)
is a database of medical information on patients withPompe disease. Physicians can use the collective informa-
tion from the registry to broaden their knowledge of the
disease, and to monitor the effectiveness of management
strategies.
Conclusions
Pompe disease is a multi-system disorder; hence it is
best managed by a multidisciplinary team, including
a metabolic disease geneticist, a physical therapist, and
other specialists according to the specific disease mani-
festations. Considering the frequent, and sometimes early,
respiratory involvement in Pompe disease, a pulmonologist
with a good knowledge of neuromuscular disease should be
included in the team. Regular pulmonary function tests and
sleep studies are mandatory.
There is a necessity to collect longitudinal patient data.
National and international registries, such as the Pompe
Disease Registry, can be useful for understanding and
monitoring this disease and the efficacy of treatment.
The recent development of a specific treatment, in the
form of enzyme replacement therapy with alglucosidase
alfa, along with other classical treatments including
physical therapy and non-invasive ventilation might
modify the natural course of the illness. This could,
therefore, lead to physicians being able to recognize and
diagnose Pompe disease as early as possible, in order to
maximize the clinical and functional benefits of
treatment.
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